Allogeneic tumor cell vaccination
US10064927B2 · kind B2 · utility
2Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 23, 2016 |
| Grant date | Sep 4, 2018 |
| Priority date | — |
| Expiry date | May 7, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/5152
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.